Biological E. Limited (BE), a Hyderabad-based Vaccine and Pharmaceutical Company, today announced the publication of Phase-III clinical trial results of BE’s 14-Valent Pneumococcal Conjugate Vaccine (PCV) (PNEUBEVAX 14TM; BE-PCV-14) conducted in paediatric population (6-8-week age group). The study results have been accepted and published by Vaccine, a reputed peer-reviewed international journal. In this study, the […] The post Biological E study finds PNEUBEVAX 14TM Vaccine Safe and effective in Infants appeared first on Healthcare India.

View Entire Post